Acamprosate calcium (BioDeep_00000839639)

   


代谢物信息卡片


Acamprosate calcium

化学式: C10H20CaN2O8S2 (400.028695)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
InChI: /q

描述信息

D002491 - Central Nervous System Agents > D000427 - Alcohol Deterrents
C26170 - Protective Agent > C1509 - Neuroprotective Agent

同义名列表

1 个代谢物同义名

Acamprosate calcium



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Ming-Fen Ho, Cheng Zhang, Lixuan Wei, Lingxin Zhang, Irene Moon, Jennifer R Geske, Michelle K Skime, Doo-Sup Choi, Joanna M Biernacka, Tyler S Oesterle, Mark A Frye, Marvin D Seppala, Victor M Karpyak, Hu Li, Richard M Weinshilboum. Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study. British journal of pharmacology. 2022 07; 179(13):3330-3345. doi: 10.1111/bph.15795. [PMID: 35016259]
  • Seon Yeong Kim, Dong Won Shin, SungIll Suh, Jae Chul Cheong, Jin Young Kim. Monitoring alcohol-use-disorder medication compliance by LC-MS/MS determination of urinary ethyl glucuronide, acamprosate, naltrexone, and 6β-naltrexol using zirconia-based hybrid solid-phase extraction. Journal of pharmaceutical and biomedical analysis. 2022 Apr; 212(?):114615. doi: 10.1016/j.jpba.2022.114615. [PMID: 35219960]
  • Ming-Fen Ho, Cheng Zhang, Lingxin Zhang, Lixuan Wei, Ying Zhou, Irene Moon, Jennifer R Geske, Doo-Sup Choi, Joanna Biernacka, Mark Frye, Zhexing Wen, Victor M Karpyak, Hu Li, Richard Weinshilboum. TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response. Molecular psychiatry. 2021 07; 26(7):3122-3133. doi: 10.1038/s41380-020-0855-9. [PMID: 32753686]
  • Murat Ozdemir, Aykut Kul, Selma Ozilhan, Olcay Sagirli. Determination of acamprosate in human plasma by UPLC-MS/MS: Application to therapeutic drug monitoring. Biomedical chromatography : BMC. 2020 Nov; 34(11):e4936. doi: 10.1002/bmc.4936. [PMID: 32602563]
  • David Wiercigroch, Hasan Sheikh, Jennifer Hulme. A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. Substance abuse treatment, prevention, and policy. 2020 01; 15(1):4. doi: 10.1186/s13011-019-0250-1. [PMID: 31931831]
  • Sonja Brünen, Nina Kim Bekier, Christoph Hiemke, Felix Korf, Klaus Wiedemann, Holger Jahn, Falk Kiefer. Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges. Alcohol and alcoholism (Oxford, Oxfordshire). 2019 Jan; 54(1):51-55. doi: 10.1093/alcalc/agy067. [PMID: 30260366]
  • Jun Pan, Rilong Jin, Miaoda Shen, Ronghuan Wu, Sanzhong Xu. Acamprosate Protects Against Adjuvant-Induced Arthritis in Rats via Blocking the ERK/MAPK and NF-κB Signaling Pathway. Inflammation. 2018 Aug; 41(4):1194-1199. doi: 10.1007/s10753-018-0766-y. [PMID: 29656315]
  • Andrea K Finlay, Laura S Ellerbe, Jessie J Wong, Christine Timko, Anna D Rubinsky, Shalini Gupta, Thomas R Bowe, Jennifer L Burden, Alex H S Harris. Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs. Journal of substance abuse treatment. 2017 06; 77(?):38-43. doi: 10.1016/j.jsat.2017.03.005. [PMID: 28476269]
  • Zhu Luo, Yali Shen, Maozhi Liang, Jia Miao, Yajun Mei, Ying Wang, Yongping Qin. Pharmacokinetics and bioequivalence evaluation of acamprosate calcium tablets in healthy Chinese volunteers. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2015 Nov; 79(?):67-72. doi: 10.1016/j.ejps.2015.09.003. [PMID: 26360834]
  • Ralitza Gueorguieva, Ran Wu, Wan-Min Tsai, Patrick G O'Connor, Lisa Fucito, Heping Zhang, Stephanie S O'Malley. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2015 Oct; 25(10):1586-99. doi: 10.1016/j.euroneuro.2015.06.006. [PMID: 26141511]
  • H W Nam, V M Karpyak, D J Hinton, J R Geske, A M C Ho, M L Prieto, J M Biernacka, M A Frye, R M Weinshilboum, D-S Choi. Elevated baseline serum glutamate as a pharmacometabolomic biomarker for acamprosate treatment outcome in alcohol-dependent subjects. Translational psychiatry. 2015 Aug; 5(?):e621. doi: 10.1038/tp.2015.120. [PMID: 26285131]
  • Małgorzata Ewertowska, Przemysław L Mikolajczak, Irena Okulicz-Kozaryn, Bogdan Stacheck, Marek Murias, Jadwiga Jodynis-Lieberti. DIFFERENT RESPONSE OF ANTIOXIDANT DEFENSE SYSTEM TO ACAMPROSATE IN ETHANOL PREFERRING AND NON-PREFERRING RATS. Acta poloniae pharmaceutica. 2015 May; 72(3):439-45. doi: ". [PMID: 26642652]
  • Craig A Erickson, Balmiki Ray, Bryan Maloney, Logan K Wink, Katherine Bowers, Tori L Schaefer, Christopher J McDougle, Deborah K Sokol, Debomoy K Lahiri. Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker. Journal of psychiatric research. 2014 Dec; 59(?):220-8. doi: 10.1016/j.jpsychires.2014.07.011. [PMID: 25300441]
  • Peter R Kufahl, Lucas R Watterson, M Foster Olive. The development of acamprosate as a treatment against alcohol relapse. Expert opinion on drug discovery. 2014 Nov; 9(11):1355-69. doi: 10.1517/17460441.2014.960840. [PMID: 25258174]
  • Jing Liang, Richard W Olsen. Alcohol use disorders and current pharmacological therapies: the role of GABA(A) receptors. Acta pharmacologica Sinica. 2014 Aug; 35(8):981-93. doi: 10.1038/aps.2014.50. [PMID: 25066321]
  • Rainer Spanagel, Valentina Vengeliene, Bernd Jandeleit, Wolf-Nicolas Fischer, Kent Grindstaff, Xuexiang Zhang, Mark A Gallop, Elena V Krstew, Andrew J Lawrence, Falk Kiefer. Acamprosate produces its anti-relapse effects via calcium. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2014 Mar; 39(4):783-91. doi: 10.1038/npp.2013.264. [PMID: 24081303]
  • Helga H Lidö, Hugh Marston, Mia Ericson, Bo Söderpalm. The glycine reuptake inhibitor Org24598 and acamprosate reduce ethanol intake in the rat; tolerance development to acamprosate but not to Org24598. Addiction biology. 2012 Sep; 17(5):897-907. doi: 10.1111/j.1369-1600.2011.00367.x. [PMID: 21955180]
  • Chinmoy Ghosh, Chandrakant P Shinde, Bhaswat S Chakraborty. Influence of ionization source design on matrix effects during LC-ESI-MS/MS analysis. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2012 Apr; 893-894(?):193-200. doi: 10.1016/j.jchromb.2012.03.012. [PMID: 22464433]
  • Lara A Ray, Kelly E Courtney, Spencer Bujarski, Lindsay M Squeglia. Pharmacogenetics of alcoholism: a clinical neuroscience perspective. Pharmacogenomics. 2012 Jan; 13(2):129-32. doi: 10.2217/pgs.11.173. [PMID: 22256863]
  • Chinmoy Ghosh, Vijay Jha, Chandrakant P Shinde, Bhaswat S Chakraborty. A LC-MS analysis of acamprosate from human plasma: pharmacokinetic application. Drug testing and analysis. 2011 Oct; 3(10):735-42. doi: 10.1002/dta.239. [PMID: 21294276]
  • F Kiefer, S H Witt, J Frank, A Richter, J Treutlein, T Lemenager, M M Nöthen, S Cichon, A Batra, M Berner, N Wodarz, U S Zimmermann, R Spanagel, K Wiedemann, M N Smolka, A Heinz, M Rietschel, K Mann. Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate. The pharmacogenomics journal. 2011 Oct; 11(5):368-74. doi: 10.1038/tpj.2010.51. [PMID: 20585342]
  • Helen Dahl, Anders Hammarberg, Johan Franck, Anders Helander. Urinary ethyl glucuronide and ethyl sulfate testing for recent drinking in alcohol-dependent outpatients treated with acamprosate or placebo. Alcohol and alcoholism (Oxford, Oxfordshire). 2011 Sep; 46(5):553-7. doi: 10.1093/alcalc/agr055. [PMID: 21616946]
  • Kyle M Kampman, Charles Dackis, Helen M Pettinati, Kevin G Lynch, Thorne Sparkman, Charles P O'Brien. A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence. Addictive behaviors. 2011 Mar; 36(3):217-21. doi: 10.1016/j.addbeh.2010.11.003. [PMID: 21112155]
  • Valentina Vengeliene, Fernando Leonardi-Essmann, Wolfgang H Sommer, Hugh M Marston, Rainer Spanagel. Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats. Biological psychiatry. 2010 Oct; 68(8):704-11. doi: 10.1016/j.biopsych.2010.05.029. [PMID: 20655511]
  • Ali Metehan Calişkan, Mustafa Naziroğlu, Abdulhadi Cihangir Uğuz, Ishak Suat Ovey, Recep Sütçü, Ramazan Bal, Sila Calişkan, Ramazan Ozcankaya. Acamprosate modulates alcohol-induced hippocampal NMDA receptors and brain microsomal Ca2+-ATPase but induces oxidative stress in rat. The Journal of membrane biology. 2010 Sep; 237(1):51-8. doi: 10.1007/s00232-010-9305-y. [PMID: 20871985]
  • Anders Hammarberg, Olof Beck, Staffan Eksborg, Nitya Jayaram-Lindström, Annika Lindefeldt, Maria Andersson, Lou Brundin, Malcolm S Reid, Johan Franck. Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: a pharmacokinetic study in healthy volunteers. Therapeutic drug monitoring. 2010 Aug; 32(4):489-96. doi: 10.1097/ftd.0b013e3181e18638. [PMID: 20592646]
  • Alexander Diehl, Lisa Ulmer, Jochen Mutschler, Hans Herre, Bertram Krumm, Bernhard Croissant, Karl Mann, Falk Kiefer. Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients. Alcohol and alcoholism (Oxford, Oxfordshire). 2010 May; 45(3):271-7. doi: 10.1093/alcalc/agq017. [PMID: 20348436]
  • Anders Hammarberg, Nitya Jayaram-Lindström, Olof Beck, Johan Franck, Malcolm S Reid. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: a randomized controlled trial. Psychopharmacology. 2009 Jul; 205(1):53-62. doi: 10.1007/s00213-009-1515-6. [PMID: 19319508]
  • Fan Xu, Yongping Qing, Beicheng Shang, Maozhi Liang, Yuangao Zou, Guili Xu. Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels. Arzneimittel-Forschung. 2009; 59(12):631-4. doi: 10.1055/s-0031-1296451. [PMID: 20108648]
  • Yun-Seok Rhee, Jeong-Hwa Park, Seok Park, Chun-Woong Park, Jeong-Myung Ha, Ki-Woo Jeong, Dong-Soo Lee, Eun-Seok Park. Analysis of acamprosate in beagle dog plasma by LC-MS-MS. Archives of pharmacal research. 2008 Aug; 31(8):1035-9. doi: 10.1007/s12272-001-1265-7. [PMID: 18787794]
  • Jadwiga Zalewska-Kaszubska, Dorota Górska, Wanda Dyr, Elzbieta Czarnecka. Effect of chronic acamprosate treatment on voluntary alcohol intake and beta-endorphin plasma levels in rats selectively bred for high alcohol preference. Neuroscience letters. 2008 Feb; 431(3):221-5. doi: 10.1016/j.neulet.2007.11.041. [PMID: 18162308]
  • T Zornoza, M J Cano-Cebrián, L Hipólito, L Granero, A Polache. Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats. Biopharmaceutics & drug disposition. 2006 Oct; 27(7):305-11. doi: 10.1002/bdd.513. [PMID: 16799924]
  • Falk Kiefer, Holger Jahn, Christian Otte, Helmut Nakovics, Klaus Wiedemann. Effects of treatment with acamprosate on beta-endorphin plasma concentration in humans with high alcohol preference. Neuroscience letters. 2006 Aug; 404(1-2):103-6. doi: 10.1016/j.neulet.2006.05.015. [PMID: 16782270]
  • Falk Kiefer, Holger Jahn, Christian Otte, Dieter Naber, Klaus Wiedemann. Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment?. Biological psychiatry. 2006 Jul; 60(1):74-6. doi: 10.1016/j.biopsych.2005.11.023. [PMID: 16483549]
  • Jadwiga Zalewska-Kaszubska, Wojciech Cwiek, Wanda Dyr, Elzbieta Czarnecka. Changes in the beta-endorphin plasma level after repeated treatment with acamprosate in rats selectively bred for high and low alcohol preference. Neuroscience letters. 2005 Nov; 388(1):45-8. doi: 10.1016/j.neulet.2005.06.032. [PMID: 16009491]
  • Avinash de Sousa, Alan de Sousa. An open randomized study comparing disulfiram and acamprosate in the treatment of alcohol dependence. Alcohol and alcoholism (Oxford, Oxfordshire). 2005 Nov; 40(6):545-8. doi: 10.1093/alcalc/agh187. [PMID: 16043433]
  • Falk Kiefer, Holger Jahn, Christian Otte, Cüneyt Demiralay, Karsten Wolf, Klaus Wiedemann. Increasing leptin precedes craving and relapse during pharmacological abstinence maintenance treatment of alcoholism. Journal of psychiatric research. 2005 Sep; 39(5):545-51. doi: 10.1016/j.jpsychires.2004.11.005. [PMID: 15992564]
  • Barbara J Mason. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. Journal of studies on alcohol. Supplement. 2005 Jul; ?(15):148-56; discussion 140. doi: 10.15288/jsas.2005.s15.148. [PMID: 16223066]
  • Anna Piorunska-Mikolajczak, Maria Piorunska-Stolzmann, Przemyslaw Mikolajczak, Irena Okulicz-Kozaryn, Ewa Kaminska. Acamprosate involvement in triacylglycerol hydrolysis and transacylation with cholesterol in chronically ethanol-drinking rats. Journal of basic and clinical physiology and pharmacology. 2004; 15(3-4):153-73. doi: 10.1515/jbcpp.2004.15.3-4.153. [PMID: 15803955]
  • Gerald P Overman, Christian J Teter, Sally K Guthrie. Acamprosate for the adjunctive treatment of alcohol dependence. The Annals of pharmacotherapy. 2003 Jul; 37(7-8):1090-9. doi: 10.1345/aph.1c351. [PMID: 12841823]
  • NULL. Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study. Alcoholism, clinical and experimental research. 2003 Jul; 27(7):1123-31. doi: 10.1097/01.alc.0000078020.92938.0b. [PMID: 12878918]
  • Bankole A Johnson, Stephanie S O'Malley, Domenic A Ciraulo, John D Roache, Robert A Chambers, Ofra Sarid-Segal, David Couper. Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. Journal of clinical psychopharmacology. 2003 Jun; 23(3):281-93. doi: 10.1097/01.jcp.0000084029.22282.bb. [PMID: 12826990]
  • Kee Namkoong, Byung-Ook Lee, Pil-Goo Lee, Moon-Jong Choi, Eun Lee. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol and alcoholism (Oxford, Oxfordshire). 2003 Mar; 38(2):135-41. doi: 10.1093/alcalc/agg038. [PMID: 12634260]
  • Barton R Harris, Mark A Prendergast, D Alex Gibson, D Trent Rogers, John A Blanchard, Robert C Holley, May C Fu, Stewart R Hart, Norman W Pedigo, John M Littleton. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcoholism, clinical and experimental research. 2002 Dec; 26(12):1779-93. doi: 10.1097/01.alc.0000042011.99580.98. [PMID: 12500101]
  • Teodoro Zornoza, Consuelo Guerri, Ana Polache, Luis Granero. Disposition of acamprosate in the rat: influence of probenecid. Biopharmaceutics & drug disposition. 2002 Oct; 23(7):283-91. doi: 10.1002/bdd.322. [PMID: 12355579]
  • Barbara J Mason, Anita M Goodman, Russell M Dixon, Magdy H Hameed, Thierry Hulot, Keith Wesnes, John A Hunter, Michael G Boyeson. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2002 Oct; 27(4):596-606. doi: 10.1016/s0893-133x(02)00368-8. [PMID: 12377396]
  • A Gual, P Lehert. Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol and alcoholism (Oxford, Oxfordshire). 2001 Sep; 36(5):413-8. doi: 10.1093/alcalc/36.5.413. [PMID: 11524307]
  • G Rubio, M A Jiménez-Arriero, G Ponce, T Palomo. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol and alcoholism (Oxford, Oxfordshire). 2001 Sep; 36(5):419-25. doi: 10.1093/alcalc/36.5.419. [PMID: 11524308]
  • K Engelhard, C Werner, H Lu, O Möllenberg, W Zieglgänsberger, E Kochs. [The neuroprotective effect of the glutamate antagonist acamprosate following experimental cerebral ischemia. A study with the lipid peroxidase inhibitor u-101033e]. Der Anaesthesist. 2000 Sep; 49(9):816-21. doi: 10.1007/s001010070054. [PMID: 11076270]
  • S Saivin, T Hulot, S Chabac, A Potgieter, P Durbin, G Houin. Clinical pharmacokinetics of acamprosate. Clinical pharmacokinetics. 1998 Nov; 35(5):331-45. doi: 10.2165/00003088-199835050-00001. [PMID: 9839087]
  • J Girault, P Gobin, J B Fourtillan. Determination of calcium acetylhomotaurinate in human plasma and urine by combined gas chromatography-negative-ion chemical ionization mass spectrometry. Journal of chromatography. 1990 Sep; 530(2):295-305. doi: 10.1016/s0378-4347(00)82333-6. [PMID: 2079505]
  • J P Lhuintre, N Moore, G Tran, L Steru, S Langrenon, M Daoust, P Parot, P Ladure, C Libert, F Boismare. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol and alcoholism (Oxford, Oxfordshire). 1990; 25(6):613-22. doi: 10.1093/oxfordjournals.alcalc.a045057. [PMID: 2085344]
  • C Chabenat, P Ladure, N Moore, P Boucly, F Boismare. Application of an analytical method to calcium acetylhomotaurinate determination in urine. Arzneimittel-Forschung. 1989 Nov; 39(11):1413-4. doi: NULL. [PMID: 2619774]